Navigation Links
BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism

NEWARK, N.J., June 12 /PRNewswire/ -- BioNeutral announced today the results of tests utilizing its Ygiene(TM) formulation to kill anthrax spores on contact. This chemical technology is designed to be used by the military and first responders in conjunction with any suspected anthrax exposure. "The Ygiene(TM) formulation killed all anthrax spores exposed to the formulation in as little as 15 seconds," said Dr. Philip Tierno, the Principal Investigator on the project. Dr. Tierno is the Director of Clinical Microbiology and Diagnostic Immunology at Tisch Hospital, New York University Medical Center. "This is an extraordinary result given the heartiness and particular difficulty in eradicating anthrax spores. The test compared results with a 10% solution of chlorine bleach which required almost 100 times the contact time to achieve the same test result. I expect this chemical technology will be used in applications which will prove beneficial, even life-saving, in hospital and other healthcare settings."

Dr. Andy Kielbania, Chief Scientist for BioNeutral, said, "We are currently continuing our corrosive and stability testing. As demonstrated by these exceptional results our combinational technology platform allows us to develop formulations that can deliver active ingredients with exceptional speed and pinpoint efficacy."

Mr. Raj Pamani, a member of the Board of Directors, said, "We look forward to introducing this technology to the Department of Homeland Security, Department of Defense and the City and State's Task Force on Bioterrorism."

About BioNeutral Laboratories Corporation

BioNeutral was organized in 2003 to commercialize a novel combinational chemistry-based technology that can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses and spores. The formulations are "Green" and include natural and common ingredients which are found in baby products and the foods we eat. These widely used compounds are combined in unique ways to create enhanced results.

BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. The products include BioNeutralizers and ChemoNeutralizers. BioNeutralizers disinfect, decontaminate and sterilize. BioNeutral believes it has the broadest-based, fastest-acting, most effective and safest antimicrobial known. This class of products has important applications for consumers, healthcare and the military. ChemoNeutralizers irreversible bind chemical contaminant and toxin molecules and render them harmless. Product applications include industrial pollution and protection against chemical weapons of mass destruction.

About Dr. Philip Tierno

Dr. Tierno is a consultant to BioNeutral. He is the Director of Clinical Microbiology and Diagnostic Immunology at Tisch Hospital, New York University Medical Center. He is also an Associate Professor at the New York University School of Medicine, NYU College of Dentistry and SUNY School of Optometry in New York City. Dr. Tierno is a member of the NYC Mayor's MRC (Medical Reserve Corps) and a former member of New York City's task force on bioterrorism. Dr. Tierno's work in the field of microbiology has resulted in numerous articles and texts that have been published in medical and scientific journals. He is co-editor and author of several books on microbes and biological protection.


Dr. Andy Kielbania

Chief Scientist

Dr. Philip Tierno


This release was issued through eReleases(TM). For more information, visit

SOURCE BioNeutral Laboratories Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Announces Management Changes
2. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
3. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
4. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
5. Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation
6. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
7. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
8. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
9. Appature Announces onKey as an Innovative Platform for Creating Microsoft HealthVault-Compatible Applications
10. Premier Research Announces Completion of Management Buyout
11. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
Post Your Comments:
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
Breaking Biology News(10 mins):